CeriBell, Inc.
Financials
Valuation Metrics
CeriBell, Inc.'s Market Cap is $1.02B. At end of 2025 it was $816M. Ranked #2405 of 3,118 in US market (top 77%), #977 of 1,474 on NASDAQ (top 66%), #153 of 203 in Health Care Equipment & Services (top 75%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.02B | US#2,405/3,118 Sec#153/203 |
| Revenue | $102M | US#2,669/3,118 Sec#184/203 |
| Net Income | $-66M | US—/3,118 Sec—/203 |
| Total Assets | $166M | US#3,008/3,118 Sec#191/203 |
| Net Assets | $128M | US#2,763/3,118 Sec#174/203 |
| Employees | 327 | US#2,384/3,118 Sec#165/203 |
| Value | ||
| P/B | 7.98x | US#2,523/3,118 Sec#159/203 |
| P/S | 10.04x | US#2,701/3,118 Sec#184/203 |
| FCF Yield | -5.50% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -51.43% | US#2,678/3,118 Sec#169/203 |
| ROA | -39.67% | US#2,938/3,118 Sec#194/203 |
| Op. Margin | -68.62% | US#2,673/3,118 Sec#185/203 |
| Revenue Growth | 31.70% | US#393/3,118 Sec#25/203 |
| Financial Health | ||
| Debt Ratio | 29.64% | US#331/3,118 Sec#34/203 |
| Total Debt | $22M | US#2,730/3,118 Sec#172/203 |
| FCF | $-56M | US#2,534/3,118 Sec#179/203 |
| Cash | $33M | US#2,727/3,118 Sec#179/203 |
| Current Ratio | 9.18x | US#275/3,118 Sec#13/203 |
| Performance | ||
| 1Y Return | 136.71% | US#76/3,118 Sec#15/203 |
| 1M Return | 13.91% | US#870/3,118 Sec#70/203 |
| From 52W High | -4.27% | US#472/3,118 Sec#45/203 |
| 1Y MDD | -30.52% | US#1,345/3,118 Sec#69/203 |
| Trading | ||
| Volume | 826,470 shares | US#2,098/3,118 Sec#148/203 |
| Trading Value | $22M | US#2,162/3,118 Sec#146/203 |
| Per Share | ||
| EPS | $-1.74 | US—/3,118 Sec—/203 |
| BPS | $3.38 | US#2,435/3,118 Sec#157/203 |
Company Info
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.